Two new Neutrogena facial sunscreens incorporate bemotrizinol, the first new sunscreen active ingredient added to the US OTC monograph in decades.
News|Articles|August 3, 2026
This Month in Derm: July 2026 Podcasts
Author(s)Marie Bosslett, Assistant Editor
This month’s podcasts highlight the latest clinical insights, emerging therapies, and evolving conversations shaping dermatology practice.
Advertisement
Advertisement
From topical steroid withdrawal and pediatric psychodermatology to skin of color representation and newborn skin barrier development, this month’s dermatology podcasts highlighted how rapidly the specialty is evolving beyond traditional clinical boundaries. Across conversations, experts emphasized a common theme: improving patient outcomes increasingly depends on understanding dermatologic disease within a broader biologic, psychosocial, and multidisciplinary context.
Related to this article
From emerging therapies to earlier intervention and psychosocial support, Dermatology Times looks back at key alopecia areata developments in 2026.
Put your dermatology expertise to the test with Dermatology Times’ interactive quiz series.
Can at-home dermarollers give the same results as in-office microneedling or is that just a myth? Read more about the latest social media trend and learn how to counsel your patients in the clinic.
The FDA approval, based on 36-week data from the phase 3 BRAVE-AA-PEDS trial, extends baricitinib access to patients as young as 12 years old with severe alopecia areata.
Guselkumab met primary and major secondary endpoints in the phase 4 STAR study, improving axial PsA symptoms and MRI-confirmed inflammation.
Find out what skin care products and aesthetic innovations clinicians are recommending to patients for the month of September.
Three experimental hair loss mechanisms are moving through late-stage trials for the first time in decades, and the data are worth knowing before patients ask.
Advertisement
Advertisement